Definition
Disease progression: the worsening or spread of a disease over time, seen as increasing severity, new or stronger symptoms, changes in biomarkers or, in cancer, tumor growth and new lesions. In clinical trials, the protocol defines exactly what counts as progression, often with standardized criteria such as RECIST 1.1, and progression is a common endpoint.
- The natural history of a disease describes how it progresses without treatment; the disease course describes what actually happens, with or without treatment.
- In solid tumors, RECIST 1.1 defines progressive disease as at least a 20 % and 5 mm increase in the sum of target lesion diameters from the smallest sum on study, or any new lesion.
- Disease models built from longitudinal data predict the course of a disease and help design better trials.
Updated October 21, 2026
Working in oncology trials? Measuring tumor response and progression with RECIST is a full section of the VIARES Oncology CRA course.
Contents
- What is disease progression?
- How fast does a disease progress?
- Stages of disease progression
- How clinical trials measure disease progression
- Disease progression in oncology: RECIST 1.1
- Example: documenting progression at a site visit
- Modeling disease progress
- Why disease progression matters in clinical research
- What a CRA checks when a participant progresses
- FAQ
- Sources
- Where you learn this at VIARES
A scan shows one lesion 3 mm larger than last time. Is that progression? Not by itself. Because progression decides whether a participant stays on study drug, trials use precise, written definitions.
What is disease progression? Meaning, disease course and natural history
Disease progression refers to a disease getting worse over time. The NCI Dictionary of Cancer Terms defines it, for cancer, as cancer that continues to grow or spread. Outside oncology, think of declining memory in Alzheimer’s disease, worsening movement in Parkinson’s disease or falling kidney function in chronic kidney disease.
Three terms are often mixed up:
- Natural history: how a disease progresses in an individual over time in the absence of treatment. CDC’s example: untreated HIV infection can take 10 years or more to progress to AIDS.
- Disease course (course of the disease): what actually happens to a patient or a population, including the effect of treatment.
- Rate of progression: how fast it happens, which is one reason trials need a control group.
The opposite of progression is response or remission; relapse means the disease returns after improvement. A sudden increase in the severity of a disease or its symptoms is usually called an exacerbation or flare. Synonyms include worsening, advancement and deterioration.
How fast does a disease progress?
The rate of progression differs between diseases and between patients. In fast-growing cancers, progression may be quick, while neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease usually progress over years. Individual factors such as age, genetic variations, other illnesses and treatment influence disease progression. Because of this heterogeneity, a clinician can rarely predict disease course at the individual level, and trials compare groups instead of single patients.
Stages of disease progression in the natural history model
There is no single official list of stages. Epidemiology courses usually teach the natural history model from CDC’s Principles of Epidemiology, which describes four stages:
| Stage | What happens | Example |
|---|---|---|
| 1. Susceptibility | Exposure to factors that can start the disease in a susceptible host | Tobacco smoke for lung cancer, a microorganism for an infection |
| 2. Subclinical disease | Pathological changes without symptoms (incubation period for infections, latency period for chronic diseases) | Lab or imaging changes before diagnosis |
| 3. Clinical disease | Symptoms begin; most diagnoses are made here | Ranges from mild to severe or fatal (the spectrum of disease) |
| 4. Recovery, disability or death | The end point of the disease process | Cure, chronic impairment or death |
The popular “5 stages” come from microbiology: OpenStax Microbiology describes five periods for acute infectious disease: incubation, prodromal, illness, decline and convalescence. Cancer staging, such as TNM, describes how far a tumor has spread at one point in time; progression describes change over time.
How clinical trials measure disease progression: longitudinal endpoints, biomarkers, neuroimaging and wearable sensors
A clinical trial cannot rely on “the patient seems worse”: the protocol names the measurement, schedule and the threshold for a clinically meaningful change.
- Time-to-event endpoints: FDA’s cancer endpoint guidance defines time to progression (TTP) as time from randomization to objective tumor progression, and progression-free survival (PFS) as time to progression or death, whichever comes first. FDA prefers PFS over TTP (see clinical endpoint).
- Clinical rating scales: repeated scores of cognition, function or disability, for example the ADAS-Cog in Alzheimer’s disease.
- Biomarkers: per the FDA-NIH BEST glossary, these are defined characteristics measured as an indicator of biological processes, pathogenic processes or responses to an intervention, such as lab values, imaging markers or neuroimaging.
- Digital measures: some studies add wearable sensors that collect continuous data between visits.
All need longitudinal data: the same measurement, compared with baseline, at planned follow-up visits. Because many diseases progress anyway, a treatment effect only shows against a placebo or standard-of-care arm that shows the expected rate of progression.
Disease progression in oncology: RECIST 1.1
Solid tumor trials usually assess progression with RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), published by Eisenhauer and colleagues in the European Journal of Cancer in 2009. At baseline, up to five target lesions (maximum two per organ) are selected and their diameters added up; each later sum is compared with earlier sums.
| Category | RECIST 1.1 definition (target lesions) | Reference |
|---|---|---|
| Complete response (CR) | All target lesions disappear; pathological lymph nodes shrink to under 10 mm short axis | n/a |
| Partial response (PR) | At least a 30 % decrease in the sum of diameters | Baseline sum |
| Stable disease (SD) | Neither enough shrinkage for PR nor enough increase for PD | Smallest sum on study |
| Progressive disease (PD) | At least a 20 % increase in the sum of diameters and an absolute increase of at least 5 mm; the appearance of one or more new lesions is also progression | Smallest sum on study (nadir), which can be baseline |
Version 1.1 added the 5 mm rule to avoid over-calling progression when sums are small.
In immunotherapy, some tumors first grow and later respond: pseudoprogression. iRECIST (Seymour et al., Lancet Oncology 2017) therefore labels first progression as unconfirmed (iUPD) until a later assessment confirms it (iCPD).
Example from trial practice: documenting progression at a site visit
Illustrative example with invented numbers. In a randomized Phase III trial with PFS as primary endpoint, a participant has three target lesions with a baseline sum of 60 mm. The sum falls to 45 mm at week 6 and 40 mm at week 12, the nadir. At week 18 it is 42 mm (stable disease), at week 24 50 mm.
Against the 40 mm nadir, 50 mm is a 25 % and 10 mm increase: progressive disease. The investigator records PD on the tumor assessment form; the participant stops study treatment per protocol and enters survival follow-up.
The key data point is the date of progression, normally the scan date. It drives the PFS analysis, so it must match across radiology report, source notes and the case report form.
Disease progression modeling in drug development: progression models, artificial intelligence and precision medicine
A disease progression model is a quantitative, mathematical model of disease progression: it describes the time course of a specific disease, built from longitudinal data. Disease progression modeling synthesizes statistics with disease knowledge and data to inform predictions and understanding of disease course in populations (DPM for short). Models range from mechanistic tumor growth models to interpretable data-driven models, and can combine longitudinal and cross-sectional data from a cohort, trials and clinical practice.
The Clinical Trials Transformation Initiative (CTTI) describes DPM as one form of model-informed drug development (MIDD) that integrates translational, clinical trial and real-world data to optimize trial design and support regulatory decisions. Each model reflects the current understanding of the disease. Uses in drug development and clinical pharmacology:
- Simulating trial duration, sample size and endpoints.
- Separating a drug’s clinical response from the natural rate of progression.
- Finding prognostic factors that raise the risk of disease progression, a step toward precision medicine and personalized medicine.
- Predicting clinical outcomes, which helps in developing effective treatments where need is unmet.
A well-known example is the Alzheimer’s disease model from the Coalition Against Major Diseases (CAMD). It describes progression on longitudinal ADAS-Cog scores in mild-to-moderate Alzheimer’s disease, was built from control-arm data of 3,179 patients, and was reviewed by both FDA and EMA in 2013 as a tool for designing trials. Researchers also train machine learning models, including deep learning, on multimodal data: biomarker data, neuroimaging, health records and wearable sensors. Combining these data types is resource-intensive, and such models need good data quality, robustness checks and validation before their predictions become actionable for a patient. CTTI’s 2024 review concluded that the potential of DPM has yet to be fully realized.
Why understanding disease progression matters for clinical research professionals
- Eligibility: oncology inclusion criteria often refer to earlier progression, for example “must have progressed within 6 months of the last treatment”.
- Safety reporting: many protocols specify that expected progression of the disease under study is captured as an efficacy outcome and is not reported as an adverse event or serious adverse event; check the protocol’s safety section for the exact rule.
- Treatment decisions: confirmed progression usually ends study treatment.
- Data integrity: missed or late scans shift the progression date and can bias PFS.
FAQ
What does disease progression mean?
Disease progression means a disease is getting worse over time: symptoms become more severe, function declines, lab values change or, in cancer, the tumor grows or spreads. In clinical trials, the protocol defines how progression is measured, for example with RECIST 1.1.
What are the 5 stages of disease progression?
Different models exist. For acute infectious disease, microbiology textbooks list five periods: incubation, prodromal, illness, decline and convalescence. Epidemiology uses CDC’s natural history model with four stages: susceptibility, subclinical disease, clinical disease, and recovery, disability or death.
What is the progression of a disease called?
The progression of a disease without treatment is called its natural history; what actually happens to a patient is the disease course. Other words for it are worsening, advancement and deterioration. A sudden increase in severity is often called an exacerbation or flare.
What does disease progression mean in cancer?
In cancer, it means the cancer continues to grow or spread. Under RECIST 1.1, progressive disease is at least a 20 % and 5 mm increase in the sum of target lesion diameters from the smallest sum on study, or any new lesion.
What is a disease progression model?
It is a mathematical model that describes how a disease changes over time, built from longitudinal patient data. In model-informed drug development, such models help simulate trials, choose endpoints and separate a treatment effect from natural progression.
Sources
- CDC: Principles of Epidemiology in Public Health Practice, Lesson 1, Section 9: Natural History and Spectrum of Disease
- OpenStax Microbiology: 15.1 Characteristics of Infectious Disease (periods of disease)
- National Cancer Institute: Definition of disease progression (NCI Dictionary of Cancer Terms)
- Eisenhauer EA et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247 (EORTC)
- Seymour L et al.: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017 (PMC)
- FDA: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Guidance for Industry (2018)
- FDA: About Biomarkers and Qualification (FDA-NIH BEST glossary categories)
- CTTI: Recent publication reviews current applications and future opportunities for disease progression modeling
- Romero K et al.: The Future Is Now: Model-Based Clinical Trial Design for Alzheimer’s Disease. Clin Pharmacol Ther (PMC)
Where you learn this at VIARES
The “RECIST” section of the VIARES Oncology CRA course covers baseline assessment, tumor burden, tumor evaluation and disease response. Learning outcomes include distinguishing RECIST 1.0 from 1.1, using oncology progression algorithms and understanding disease progression; the assignment asks you to explain iRECIST, why a non-target lesion cannot later become a target lesion, and the pitfalls of RECIST.
